Skip to main content

Grafa News and Videos — Page 1211

Latest

Grafa

Enhertu secures positive EU panel backing for first pan-tumor HER2 therapy

Enhertu (trastuzumab deruxtecan) moved a step closer to a milestone regulatory approval in Europe, securing a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) as a tumor-agnostic treatment for advanced solid malignancies.

Read more: Enhertu secures positive EU panel backing for first pan-tumor HER2 therapy
Grafa

AbbVie secures positive EU panel backing to expand Maviret to acute Hepatitis C

AbbVie (NYSE:ABBV) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Maviret (glecaprevir/pibrentasvir) for the treatment of acute hepatitis C virus (HCV) infection.

Read more: AbbVie secures positive EU panel backing to expand Maviret to acute Hepatitis C
Grafa

BioLineRx and Hemispherian to showcase preclinical data for first-in-class glioblastoma asset at ASCO 2026

BioLineRx (NASDAQ:BLRX) and Hemispherian announced that two abstracts featuring their experimental oncology compound, GLIX1, will be published at the upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting.

Read more: BioLineRx and Hemispherian to showcase preclinical data for first-in-class glioblastoma asset at ASCO 2026
Grafa

ImmunityBio data highlights highly individualized patient priorities in bladder cancer care

ImmunityBio (NASDAQ:IBRX) announced new survey data highlighting the highly individualized treatment preferences and quality-of-life priorities of patients navigating high-risk non-muscle-invasive bladder cancer (NMIBC).

Read more: ImmunityBio data highlights highly individualized patient priorities in bladder cancer care
Grafa
Retail

BJ’s Wholesale net income dips to $142.7M as expansion costs offset membership Gains

BJ’s Wholesale Club Holdings (NYSE:BJ) reported a slight decline in first-quarter net income, as aggressive pricing strategies and rising overhead from footprint expansion offset resilient gains in membership fee revenue.

Read more: BJ’s Wholesale net income dips to $142.7M as expansion costs offset membership Gains

GET YOUR GRAFA EDGE NOW

We'll switch on a 30-day Edge trial as a welcome gift